Statistics from Altmetric.com
A recent publication from the UNICEF baby friendly initiative1 particularly identifies ‘use of maternal beta-blockers such as Labetalol’ as a risk factor for neonatal hypoglycaemia. Labetalol is a combined α- and β-adrenoreceptor that decreases peripheral vascular resistance without significant alteration of heart rate or cardiac output. It has been used to treat pregnancy-induced hypertension and although there have been isolated reports of neonatal hypoglycaemia in association with maternal labetalol treatment, these …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.